Johnson & Johnson Reports Updated MajesTEC-1 Data for Tecvayli in Multiple Myeloma

Johnson & Johnson today presented updated two-year follow-up data from the MajesTEC-1 trial evaluating Tecvayli (teclistamab-cqyv) in patients with relapsed or refractory multiple myeloma. The data showed that responses were durable, with a median duration of response of 24.1 months in patients who achieved a complete response or better.